end market product launch ad growth
maintain buy rate upgrad tp
previous tp base forward price-to-earnings
multipl adjust ep
provid upsid potenti
estim base follow factor strong
growth revenu earn new product launch
acquisit gatan growth
emerg market
deliv strong result quarter revenu
increas growth due
growth across busi segment strong growth
emerg market saw strong momentum china
growth quarter ep increas
adjust ep increas
life scienc solut segment revenu increas
due strong growth clinic next-gen sequenc
bioproduct bioscienc genet scienc
analyt instrument segment revenu increas
due strong growth across busi
segment chemic analysi chromo mass spec electron
laboratori product servic segment includ
patheon acquisit report revenu increas
growth due clinic trial logist busi
research safeti market channel
compani namethermo fisher scientif inctickertmostock ratingbuyunchangedindustri viewoverweightpositivepric sep week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth thermo fisher scientific| septemb
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
specialti diagnost segment revenu grew
quarter strong growth transplant diagnost
clinic diagnost busi also healthcar
launch suit new mass spectrometri system
thermo scientif exact uhmr protein research
also launch ion torrent oncomin childhood
cancer research assay thermo scientif
 kryptor gold immunoassay analyz europ
open new precis medicin scienc center
 give custom greater access rang
technolog expertis offer
announc agreement acquir gatan inc lead
provid instrument softwar enhanc
perform electron microscopi system
expect revenu
revenu growth
adjust ep estim
repres growth
current price-to-earnings
due stock market momentum quarter
price-to-earnings averag price-to-earnings
price-to-earnings fallen
consid strong growth expect forward price-to-earnings
expect top-lin revenu grow
consid organ growth
recommend buy rate base perform
new product launch period
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date oct ex-dividend date sep last split factor new per last split date jun inform thermo fisher scientific| septemb
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer pg
incom statement item total gross research develop sell gener administr sg oper depreciation- oper profit incom special charges- interest interest incom incom incom net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli thermo fisher scientific| septemb
 market account receivable- total prepaid expenses- current total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer current liabilities- total current long-term defer incom non-curr minor interest total non-curr total prefer stock equity- common stock addit paid-in retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item thermo fisher scientific| septemb
provid oper activ provid incom off-set
part invest work capit payment restructur action princip sever cost
leas expens real estat consolid use cash
tmo invest activ use cash acquisit use cash
purchas properti plant equip use cash
financ activ use cash repay senior note use cash
financ activ also includ payment cash dividend off-set part
net proce employe stock option exercis
depreciation- defer incom oper gains- increas decreas increas decreas current assets- decreas increas decreas increas current liabilities- decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant purchas properti plant net invest financ activitiesissu issuanc capit repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end thermo fisher scientific| septemb
deliv strong quarterli result reflect strength global
competit posit strong perform due growth end
market new product launch
thermo fisher total revenu increas
compar organ revenu growth
quarter acquisit increas revenu currenc translat
increas revenu total product revenu increas
compar total servic revenu increas
compar
product revenu increas compar
servic revenu increas
compar cog sale
compar
sg expens increas compar
sg expens total revenu compar
total revenu
revenu increas
compar
compar
 expens increas compar
 expens total revenu compar
total revenu restructur cost decreas
compar
oper incom increas compar
oper margin compar
adjust oper incom increas
adjust oper margin increas
oper incom due profit higher sale local currenc
effect acquisit
effect tax rate compar net
incom increas compar
ep increas compar
adjust ep increas
total revenu increas compar
total product revenu increas
compar total servic revenu increas
compar
cost product revenu increas compar
cost servic revenu increas
compar cog revenu
compar
sg expens increas compar
sg expens revenu compar
compar
compar
 expens increas compar
 expens revenu compar
restructur cost increas
compar
oper incom increas compar
oper margin compar
effect tax rate compar net
incom increas compar
ep increas compar
revenu geograph region
total revenu
total revenu europ
total revenu asia-pacif region
total revenu region
revenu end-market
pharma deliv mid-teen growth
diagnost healthcar grew mid-singl digit
industri appli deliv mid-singl digit growth
quarter due continu strong custom demand analyt instrument
academ govern grew high-single-digit
total revenu
industri appli
singl digit growth
quarter due continu
analyt instrument
provid analyt instrument equip reagent consum
softwar servic research manufactur analysi discoveri
diagnost oper four segment life scienc solut analyt
instrument specialti diagnost laboratori product servic
total revenu ai segment increas
compar total revenu increas
compar
sale increas due higher revenu exist busi
due favor effect currenc translat due
acquisit increas revenu exist busi due
increas demand product sold segment chromatographi
mass spectrometri busi electron microscopi busi chemic
total revenu
ai segment increas
compar
increas revenu
ai segment
due increas demand
product sold
chromatographi
microscopi busi
oper margin compar
increas due profit higher sale local currenc product
improv net inflationari cost increas off-set strateg
laboratori product servic segment lp
total revenu lp segment increas
compar total revenu increas
compar
sale increas due acquisit due higher
revenu exist busi due favor effect
currenc translat increas revenu exist busi due
increas demand product sold segment research
safeti market channel busi servic offer clinic trial
oper margin compar
decreas due unfavor sale mix strateg invest off-set
part profit higher sale local currenc
total revenu lss segment increas
compar total revenu increas
compar
sale increas due higher revenu exist busi
due favor effect currenc translat due
acquisit increas revenu exist busi due
increas demand segment princip busi particularli
bioscienc product bioprocess product product genet scienc
product clinic next-gener sequenc product
total revenu
compar
total revenu
compar
total revenu lss segment increas
compar total revenu increas
compar
total revenu lss
segment increas
compar
sale increas due higher revenu exist busi
due favor effect currenc translat due
acquisit increas revenu exist busi due
increas demand segment princip busi particularli
bioscienc product bioprocess product product genet scienc
product clinic next-gener sequenc product
oper margin compar
increas due profit higher sale local currenc
total revenu special diagnost segment increas
compar total revenu
increas compar
sale increas due higher revenu exist busi
due favor effect currenc translat due
acquisit increas revenu exist busi due
higher demand particular strength sale product sold
segment healthcar market channel clinic diagnost product
oper margin flat increas due profit
higher sale local currenc favor foreign currenc exchang
off-set strateg growth invest
total revenu
segment increas
compar
thermo fisher rais revenu earn guidanc reflect strong
oper perform partial off-set less favor foreign exchang
expect revenu
growth
adjust ep
growth
agreement acquir
provid
instrument
softwar enhanc
perform electron
expect revenu
revenu growth
adjust ep estim repres
growth
deliv strong quarterli perform due growth end market
revenu grew ep increas
adjust ep increas
launch suit new mass spectrometri system life scienc
appli market thermo scientif exact uhmr protein research
also launch new product clinic research diagnost includ
ion torrent oncomin childhood cancer research assay thermo
scientif kryptor gold immunoassay analyz europ
open new precis medicin scienc center give
custom greater access rang technolog expertis
offer help acceler develop individu patient treatment
announc agreement acquir gatan inc lead provid
instrument softwar enhanc perform electron
tmo perform reflect strength global competit
non- reconcili
non- reconcili
non- reconcili
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin declin ttm compar due increas cog
revenu growth ttm compar
ep growth ttm compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth thermo fisher scientific| septemb
mrqgross mrqcog mrqnet mrqsg mrqr sale thermo fisher scientific| septemb
inv flow sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset thermo fisher scientific| septemb
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer dividends- annual itemsquarterli item thermo fisher scientific| septemb
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant purchas sale purchas investment- sale issuanc repurchas stock- net issuanc prefer stock- net issuanc net chang capit free thermo fisher scientific| septemb
current price-to-earnings due stock market momentum
quarter price-to-earnings averag price-to-earnings price-to-earnings fallen
consid strong growth expect forward price-to-earnings
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold direct holder form marc peter scott andrew alan thoma jim patrick institut holdersholdershar report outvaluevanguard group inc massachusett servic capit research global capit world price row associ wellington manag compani america fmr top mutual fund holdersholdersharesd report outvaluevanguard total stock market growth fund america vanguard amcap spdr etf vanguard institut fund-institut vanguard specialized-health fundament investor mf seri trust i-mf valu ishar thermo fisher scientific| septemb
developmentsthermo fisher scientif bring benefit feg new desktop scan electron microscopethethermo scientif phenom pharo desktop scan electron microscop first desktop solut thermo fisher scientif includ field emiss gun feg phenom pharo microscop easi oper incorpor advanc hardwar design fast time-to-imag simpl handl wide rang academ industri research access benefit feg desktop model increas throughput new electron backscatt diffract ebsd detector featur advanc sensor opticsa new electron backscatt diffract ebsd detector electron microscopi design help scientist research engin quickli accur identifi new materi understand structur materi affect properti detector combin advanc optic new sensor collect megapixel largest number pixel ebsd detector market new tripl quadrupol mass spectromet offer robust analysi lc-ms/m clinic research laboratoriesth thermo scientif tsq forti tripl quadrupol mass spectromet along liquid chromatographi instrument design applic demand optim blend speed robust class-lead sensit quantit compound biolog matric user vari level expertis new thermo scientif brahm kryptor gold analyz instrument combin higher throughput autonomyscientist work clinic research laboratori access autom analyz blood sampl test superior precis effici new brahm kryptor gold develop alreadi establish benchtop instrument kryptor compact allow facilit handl increas capac blood sampl reagent consum previou kryptor analyz new kryptor gold incorpor trace time resolv amplif cryptat emiss technolog maintain standard precis necessari diagnosi prognosi human diseas basic principl trace synthesi cryptand provid basi nobel prize chemistri august thermo fisher scientific| septemb
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
compar
gross margin ttm
compar
industri averag
roa roe roi
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit thermo fisher scientific| septemb
consensu view analyst trend stock
forecast
lower
growth rate
forward price-to-earnings
higher
valuat comparisontmoindustri avg avgprice/earn yield avgfive-year growth forecast usdgrowth high day day day estim thermo fisher scientific| septemb
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr
next qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr analyst recommend
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock price show upward trend sinc mid-juli reach
averag volum share trade period gave return
quarter
stock price show upward momentum past one year volatil
stock gave return past rang
stock price given return past shown increas momentum sinc
growth stock price due tmo strong perform growth emerg market
thermo fisher scientif deliv strong revenu earn growth launch new
product strong growth emerg market maintain buy rate stock tp
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
